FDA clears first long-act­ing HIV-pre­ven­tion in­jectable, giv­ing Vi­iV claim to his­toric OK

A long-act­ing in­jectable treat­ment for the pre­ven­tion of HIV has been giv­en the go-ahead by the FDA for use in adults and chil­dren weigh­ing at least 77 pounds.

Apre­tude is first giv­en as two in­jec­tions giv­en a month apart from each oth­er, and then every two months af­ter. Pa­tients are giv­en the op­tion to start treat­ment with Apre­tude or the oral cabote­gravir Vo­cabria for four weeks to as­sess how well to tol­er­ate the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.